Table 3.
Nested case–control study to assess the association between ULT use and TJR among patients with gout
| Use of uric acid drugs | Taiwan cohort | UK cohort | ||||
|---|---|---|---|---|---|---|
| THR, adjusted OR (95% CI) | TKR, adjusted OR (95% CI) | TJR, adjusted OR (95% CI) | THR, adjusted OR (95% CI) | TKR, adjusted OR (95% CI) | TJR, adjusted OR (95% CI) | |
| Xanthine oxidase inhibitors | ||||||
| <28 cDDD | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 28–≤90 cDDD | 1.03 (0.74, 1.44) | 1.06 (0.75, 1.50) | 1.06 (0.83, 1.34) | 1.13 (0.82, 1.56) | 0.93 (0.62, 1.40) | 1.09 (0.83, 1.42) |
| 91–≤180 cDDD | 0.92 (0.52, 1.62) | 0.91 (0.54, 1.52) | 1.02 (0.70, 1.50) | 1.36 (0.92, 2.02) | 0.69 (0.43, 1.11) | 0.93 (0.68, 1.27) |
| >180 cDDD | 1.27 (0.74, 2.20) | 0.75 (0.43, 1.33) | 1.25 (0.83, 1.88) | 1.02 (0.85, 1.22) | 1.01 (0.83, 1.22) | 1.08 (0.94, 1.24) |
| P for trend | 0.57 | 0.42 | 0.31 | 0.59 | 0.88 | 0.34 |
| Uricosuric agentsa | ||||||
| <28 cDDD | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | NA | NA | NA |
| 28–≤90 cDDD | 0.91 (0.73, 1.13) | 0.97 (0.78, 1.20) | 0.89 (0.77, 1.04) | NA | NA | NA |
| 91–≤180 cDDD | 0.98 (0.73, 1.30) | 0.95 (0.70, 1.27) | 1.00 (0.81, 1.23) | NA | NA | NA |
| >180 cDDD | 0.96 (0.73, 1.27) | 1.16 (0.89, 1.52) | 1.04 (0.86, 1.26) | NA | NA | NA |
| P for trend | 0.67 | 0.48 | 0.93 | NA | NA | NA |
| Urate-lowering therapy | ||||||
| <28 cDDD | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | NA | NA | NA |
| 28–≤90 cDDD | 0.89 (0.72, 1.10) | 0.98 (0.79, 1.20) | 0.89 (0.77, 1.03) | NA | NA | NA |
| 91–≤180 cDDD | 0.99 (0.76, 1.30) | 1.03 (0.79, 1.35) | 1.03 (0.85, 1.24) | NA | NA | NA |
| >180 cDDD | 1.04 (0.81, 1.33) | 1.09 (0.85, 1.40) | 1.12 (0.94, 1.34) | NA | NA | NA |
| P for trend | 0.91 | 0.53 | 0.36 | NA | NA | NA |
a
ORs and 95% CIs estimated by conditional logistic regression analysis and adjusted for socio-economic status, Charlson co-morbidity index, co-morbidities and co-medications in the Taiwan cohort and Charlson co-morbidity index, BMI, smoking status, alcohol consumption, co-morbidities and co-medications in the UK cohort.
*P < 0.05.